Vanguard Capital Management’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$15.3M Sell
1,578,165
-12,356
-0.8% -$143K ﹤0.01% 2534
2026
Q2
$18.5M Sell
1,590,521
-29,342
-2% -$419K ﹤0.01% 2484
2026
Q1
$27.2M Buy
+1,619,863
New +$29M ﹤0.01% 2180

Other funds holding CLB

Vanguard Capital Management's CLB Position: Q3 2026 in Review

Vanguard Capital Management reduced its Core Laboratories (CLB) stake by 0.78% in Q3 2026, selling an estimated $143K and leaving 1,578,165 shares worth $15.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2534.

Vanguard Capital Management first reported a position in CLB in Q1 2026 and has held it in 3 quarters since. The position peaked at $27.2M in Q1 2026. 180 funds tracked by Wall St. Rank hold CLB as of Q3 2026.

  • Vanguard Capital Management held 1,578,165 shares of Core Laboratories worth $15.3M as of Q3 2026.
  • Vanguard Capital Management sold 12,356 Core Laboratories shares in Q3 2026, an estimated $143K.
  • Core Laboratories made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2534 holding.
  • Vanguard Capital Management first reported a position in Core Laboratories in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Core Laboratories position peaked at $27.2M in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.